• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

sanofi

Research highlights cost savings from DarioHealth digital diabetes therapeutic

July 26, 2023 By Sean Whooley

DarioHealth

DarioHealth (Nasdaq:DRIO) announced today that a new analysis demonstrated a significant cost reudction for users of its digital therapeutic platform. Sanofi U.S. conducted the analysis, which showed lower costs of care for DarioHealth users compared to non-users with type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings […]

Filed Under: Clinical Trials, Diabetes, Technology Tagged With: dariohealth, sanofi

Glooko, Sanofi partner on insulin pen connectivity

February 23, 2023 By Sean Whooley

Sanofi DoubleStar SoloStar Toujeo Glooko SoloSmart

Glooko announced today that it entered into a partnership with Sanofi to integrate a connected device for insulin pens into its digital platform. SoloSmart, a single-piece, add-on connected device works with Sanofi’s SoloStar and DoubleStar insulin injection pens. It records the insulin dose, date and time of injection. Through this partnership, the company’s can offer […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: glooko, sanofi

Digital therapeutics open up new opportunities in medicine

May 5, 2022 By Sean Whooley

Pear Therapeutics reSET_Check_In (1)

A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]

Filed Under: Business/Financial News, Neurological, Technology Tagged With: Better Therapeutics, dariohealth, Pear Therapeutics, sanofi

Gyroscope Therapeutics to receive investment from Sanofi worth up to $60M

November 8, 2021 By Sean Whooley

Gyroscope Therapeutics

Gyroscope Therapeutics announced today that it received a commitment from Sanofi (NYSE:SNY) to invest up to $60 million. London-based Gyroscope will receive a $40 million investment from Sanofi initially. That $40 million represents a premium to Gyroscope’s previous Series C financing, with the remaining $20 million to be invested contingent on a future qualifying investment […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals Tagged With: Gyroscope Therapeutics, sanofi

Sanofi to acquire Kadmon for $1.9B

September 8, 2021 By Sean Whooley

sanofi kadmon

Sanofi (NYSE:SNY) announced today that it entered into a definitive merger with therapeutic developer Kadmon (NSDQ:KDMN) for $1.9 billion. The acquisition adds Rezurock (belumosudil), a recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease (cGVHD) for patients over 12 years old who have failed at least two prior lines of systemic therapy, to Sanofi’s transplant portfolio. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions Tagged With: kadmon, sanofi

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

Pharma 50 50 largest pharma companies pharmaceutical

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Featured, Pharmaceuticals Tagged With: AstraZeneca plc, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer Inc., Pharma 50, Roche, sanofi, Sinopharm

Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system

May 10, 2021 By Sean Whooley

Bigfoot Biomedical smart insulin pen cap

Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system. Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release. Bigfoot Unity smart pen caps offer on-demand […]

Filed Under: Auto-injectors, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: abbott, Bigfoot Biomedical, Eli Lilly & Co., Novo Nordisk, sanofi

Global wearable patch market growing at 10.6% rate

February 22, 2021 By Sean Whooley

G6

Researchers say that the global wearable patch market size is expected to reach $12.6 billion by 2026, marking a massive rise over five years. According to the research, put together by ResearchAndMarkets.com, the rise is expected to represent a compound annual growth rate of 10.6% during the forecast period. Wearables covered by the research, including […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: abbott, Dexcom, Eli Lilly & Co., Insulet, sanofi, wearables

Abbott, Medtronic ink diabetes pacts with Sanofi, Novo Nordisk

September 16, 2019 By Danielle Kirsh

abbott-sanofi-medtronic-novo-nordisk

Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) today announced separate data-sharing deals for digital diabetes management solutions. Abbott is partnering with Sanofi (NYSE:SNY) to integrate glucose sensing and insulin delivery to help people manage their diabetes. The two companies plan to develop tools to combine Abbott’s FreeStyle Libre technology with insulin dosing information for smart pens, insulin titration apps and […]

Filed Under: Diabetes, Diagnostics, Patient Monitoring Tagged With: abbott, Medtronic, Novo Nordisk, sanofi

Biocorp, Sanofi ink €4m Mallya sensor deal

July 3, 2019 By Brad Perriello

Sanofi, Biocorp

Biocorp (PAR:ALCOR) said today that it inked a deal with pharma giant Sanofi (NYSE:SNY) to integrate its Mallya sensor into Sanofi’s diabetes management platform. Issoire, France-based Biocorp’s Mallya is designed to clip to an injection pen to automatically log and transmit dosage data. The deal calls for Sanofi to pay Biocorp €4 million, or about $4.5 […]

Filed Under: Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: biocorp, sanofi

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS